Analisis Efektivitas Biaya Pasien PROLANIS DM Tipe 2 di Puskesmas Kota Bandung

Cost Effectiveness Analysis of PROLANIS Patients with DM Type 2 at Bandung Health Centers

Authors

  • Ulyati Ulfah Universitas Padjadjaran
  • Eli Halimah Program Studi Magister Farmasi Klinik Fakultas Farmasi Universitas Padjadjaran
  • Auliya A Suwantika Program Studi Magister Farmasi Klinik Fakultas Farmasi Universitas Padjadjaran

DOI:

https://doi.org/10.25026/jsk.v4i1.761

Keywords:

BPJS, Cost Effectiveness, DM, FKTP, Prolanis

Abstract

Diabetes mellitus is one of chronic diseases with high treatment cost. Purpose of this research was to analyze the cost-effectiveness of (Prolanis) for patients with type 2 DM and to establish the most significance parameter affecting the cost-effectiveness value. This study is a non-experimental retrospective by collecting medical record data of Prolanis patients with type 2 DM at Bandung Health Center during 2015 and 2016 with 246 samples that met the inclusion criteria. Cost-effectiveness analysis was conducted by calculating Average Cost Effectiveness Ratio (ACER) and Incremental Cost Effectiveness Ratio (ICER). In particular, sensitivity analysis was conducted to investigate the most significance parameter affecting those ratios. The result of unpaired t test confirmed that there was not significance difference on ACER values of 2015 and 2016, whereas the value of arithmetic (0,202) < t table (4,303) with significance value ? 0,04 <0,05. The implementation of Prolanis in 2015 (ACER = Rp. 1.095,97) seemed to be more cost effective than in 2015 (ACER = Rp. 1.268,96). Cost of biguanida drugs is the most influential factor affecting the cost-effectiveness values of Prolanis implementation in patients with type 2 DM in 2015 and 2016.

References

Daftar Pustaka

[1] U. Galicia-Garcia et al., “Pathophysiology of Type 2 Diabetes Mellitus,” Int. J. Mol. Sci., vol. 21, no. 17, pp. 1–34, 2020, doi: 10.3390/ijms21176275.
[2] T. Kocsis et al., “Probiotics Have Beneficial Metabolic Effects in Patients With Type 2 Diabetes Mellitus: a Meta-Analysis of Randomized Clinical Trials,” Sci. Rep., vol. 10, no. 1, pp. 1–14, 2020, doi: 10.1038/s41598-020-68440-1.
[3] T. A. Zelniker et al., “Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial,” Circulation, pp. 1227–1234, 2020, doi: 10.1161/CIRCULATIONAHA.119.044183.
[4] L. Pranata, S. Indaryati, and N. E. Daeli, “Perangkat Edukasi Pasien dan Keluarga dengan Media Booklet (Studi Kasus Self-Care Diabetes Melitus),” J. Keperawatan Silampari, vol. 4, no. 1, pp. 102–111, 2020, doi: 10.31539/jks.v4i1.1599.
[5] N. J. Nugraha and R. Rahmat, “Implementasi Metode Support Group Dalam Meningkatkan Persepsi Pasien Tentang Perawatan Diabetes Melitus di Kota Bandung,” Faletehan Heal. J., vol. 7, no. 1, pp. 62–67, 2020, doi: 10.33746/fhj.v7i1.123.
[6] W. Riniasih and W. . Hapsari, “Hubungan Tingkat Pendidikan Peserta Prolanis Dengan Peningkatan Kualitas Hidup Penderita Diabetes Melitus di Fktp Purwodadi,” vol. 5, no. 1, pp. 1–8, 2020.
[7] M. Fathurrahman, A. Suwantika, and R. Hendriani, “Analisis Efektivitas Biaya Program Pengelolaan Penyakit Kronis (PROLANIS) terhadap Penyakit Hipertensi di Puskesmas Kota Bandung,” vol. IX, no. 1, pp. 61–74, 2020.
[8] R. Afifah, Y. Riza, and Z. Anwar, “Deterimnan tingkat kepatuhan peserta program pengelolaan penyakit kronis (prolanis) diabetes melitus tipe 2 di puskesmas pemurus baru kota banjarmasin,” 2020.
[9] Y. R. D. N. Septian. A.A, “Cost Effectiveness Analysis Antibiotik Seftriakson dan Sefotaksim pada Pasien Anak Rawat Inap Demam Tifoid di Rumah Sakit PKU Aisyiyah Boyolali,” vol. 2017, no. 1, pp. 1–9, 2020.
[10] D. D. Kim, M. C. Silver, N. Kunst, J. T. Cohen, D. A. Ollendorf, and P. J. Neumann, “Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018,” Pharmacoeconomics, vol. 38, no. 10, pp. 1135–1145, 2020, doi: 10.1007/s40273-020-00942-2.
[11] K. R. Siegel et al., “Cost-effectiveness of interventions to manage diabetes: Has the evidence changed since 2008?,” Diabetes Care, vol. 43, no. 7, pp. 1557–1592, 2020, doi: 10.2337/dci20-0017.
[12] A. Apoorva, G. K, and A. D, “A comparison of cost-effectiveness between doxycycline and azithromycin with topical clindamycin in the treatment of patients with moderate to severe acne vulgaris: Prospective, randomized study,” Natl. J. Physiol. Pharm. Pharmacol., vol. 10, no. 0, p. 1, 2020, doi: 10.5455/njppp.2020.10.02038202013022020.
[13] J. Wang, M. A. Lee Bravatti, E. J. Johnson, and G. Raman, “Daily almond consumption in cardiovascular disease prevention via LDL-C change in the U.S. population: A cost-effectiveness analysis,” BMC Public Health, vol. 20, no. 1, pp. 1–10, 2020, doi: 10.1186/s12889-020-08642-4.
[14] I. Aznar-Lou et al., “Cost-effectiveness analysis of a multiple health behaviour change intervention in people aged between 45 and 75?years: a cluster randomized controlled trial in primary care (EIRA study).,” Int. J. Behav. Nutr. Phys. Act., vol. 18, no. 1, p. 88, 2021, doi: 10.1186/s12966-021-01144-5.
[15] S. Syabriyantini, R. Susanti, P. S. Farmasi, F. Kedokteran, and U. Tanjungpura, “Cost-Effectiveness of Ampicillin and Cefotaxime Used by Pediatric Patients with Typhoid Fever,” J. Media Kesehat. Masy. Indones., vol. 13, no. 2, pp. 131–138, 2017.
[16] N. Isnani, M. Muliyani, M. Zaini, and M. Arif Riyadi, “Analisis Efektivitas Biaya (Cost-Effectiveness) Penggunaan Antidiabetes Oral Kombinasi pada Pasien Diabetes Melitus Tipe Ii Rawat Jalan Di Rsud Dr. H. Moch. Ansari Saleh Banjarmasin,” J. Insa. Farm. Indones., vol. 4, no. 1, pp. 103–110, 2021, doi: 10.36387/jifi.v4i1.683.
[17] I. R. Ramadhan, W. Syurya, and T. Dharma, “Monoterapi Dan Kombinasi Pada Pasien Diabetes Rumah Sakit Islam Cempaka Putih Jakarta Periode Analysis of the Effectiveness of Monotherapy Antidiabetic Medicine and Combination in Diabetes Melitus Patient Ii Type Ii Participants of Bpjs Patients in Hospit,” vol. 5, no. 1, pp. 34–47, 2020.
[18] R. Cookson et al., “Using Cost-Effectiveness Analysis to Address Health Equity Concerns,” Value Heal., vol. 20, no. 2, pp. 206–212, 2017, doi: 10.1016/j.jval.2016.11.027.

Downloads

Published

2022-02-28

How to Cite

Ulfah, U., Halimah, E., & Suwantika, A. A. (2022). Analisis Efektivitas Biaya Pasien PROLANIS DM Tipe 2 di Puskesmas Kota Bandung: Cost Effectiveness Analysis of PROLANIS Patients with DM Type 2 at Bandung Health Centers. Jurnal Sains Dan Kesehatan, 4(1), 19–27. https://doi.org/10.25026/jsk.v4i1.761

Most read articles by the same author(s)